An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression

Trial Profile

An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Postnatal depression
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 28 Mar 2016 According to Sage media release, the company will present data from this study at the Society of Biological Psychiatry 71st Annual Scientific Meeting.
    • 12 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 09 Jun 2015 Top-line results published in a SAGE Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top